Kangfang Biotech's innovative drug Yivoksizumab (trade name: Yidafang®) has been approved by the National Medical Products Administration for a new...
-
-
Recent Updates
- China’s Technological Showcase: Shenzhen to Host APEC 2026
- “BlackDiamonds Are Forever”: LightPath Technologies Capitalizing on China-Driven Germanium Squeeze
- Microsoft’s Strategic Moves in China Amid Geopolitical Tensions
- Innovative Drug Yivoksizumab (trade name: Yidafang®) Approved for New Indication in First-Line Treatment of Advanced Squamous Cell Lung Cancer
- Biolink Science and ACROBiosystems Forge Strategic Partnership to Develop AI-Powered Next-Generation Affinity Purification Solutions
- Propelis Strengthens Presence in Greater China to Boost Brand Localization and Speed
- Chinese Automakers Accelerate Overseas Expansion with Mobileye Dominating Front-view Integrated Chip Market
- TÜV South Germany and Saibao Strengthen UN R171 Testing Certification Collaboration for Global Access to Smart Driving
- Shein Plans Hong Kong IPO Amid Valuation Challenges
- Tesla to run reduced output in Shanghai in January, plan shows
Blogroll